Leukapheresis Industry worth $100 million by 2028

Leukapheresis Market in terms of revenue was estimated to be worth $70 million in 2023 and is poised to reach $100 million by 2028, growing at a CAGR of 8.3 % from 2023 to 2028 according to a new report by MarketsandMarkets™. The global leukopaks market is anticipated to reach USD 1020 million by 2028 from USD 200 million in 2023, at a CAGR of 38.1%. The leukopaks market is driven by the increasing demand for leukopaks in research applications, such as the development of new cancer treatments. The demand for leukopaks is growing due to the increasing number of research studies being conducted on cancer. The development of new cancer treatments is also driving the demand for leukopaks. Other factors that are contributing to the growth of the leukopaks market include the increasing incidence and prevalence of cancer, the growing popularity of personalized medicine, advances in medical technology, and growing awareness about leukopaks and their benefits in developing nations.

Download an Illustrative overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148

Browse in-depth TOC on "Leukapheresis Market"

230 - Tables

80 - Figures

295 – Pages

In this report, the overall leukapheresis market is divided into the leukapheresis products market and the Leukopaks Market. The leukapheresis products Market is classified into segments including type, application, end user, and region, and the leukopaks Market is classified into segments such as type, indication, end user, and region.

The disposables segment accounted for the larger share of the leukapheresis products industry.

By type, the leukapheresis products market can be segmented into devices and disposables. The disposables segment occupied a larger share of the leukapheresis products market in 2022. The disposables used in leukapheresis procedures are products used to access blood vessels and store blood components, replacement fluids, and anticoagulants to prevent blood from clotting in the process. Disposables are used for both automated blood collection and therapeutic leukapheresis. They include apheresis catheters, needle sets, centrifuge bowls, tubing sets/pipeline systems, collection bags, and various solutions such as saline, anticoagulants, media, columns, filters, and cell separation kits.

The mobilized leukopaks segment dominated the leukopaks industry based on type.

By type, the leukopaks market is categorized into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. The mobilized leukopaks segment dominated the leukopaks market in 2022. Mobilized leukopaks are mainly used in preclinical and clinical research in a variety of fields, including cancer immunotherapy, cell therapy, and regenerative medicine. Charles River Laboratories (US), Discovery Life Sciences (US), StemExpress (US), BioIVT (US), and Caltag Medsystems (UK) are some of the major players offering mobilized leukopaks for research and clinical applications.

North American region dominated the Leukapheresis market with the largest market share.

The Leukapheresis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America reported the largest share of the Leukapheresis market in 2022. The incidence and prevalence of leukemia are increasing in North America, due to factors such as environmental pollution, exposure to radiation, and unhealthy lifestyle habits. This is driving the demand for leukapheresis products, which are used to treat leukemia.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=20283148

Leukapheresis Market Dynamics:

Drivers:

Increased demand for leukopaks in clinical research

Restraints:

Complications associated with therapeutic leukapheresis

Opportunities:

Gaps in current leukapheresis technologies

Challenges:

Blood transfusion safety in developing countries

Key Market Players:

Key players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany). Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US). These companies adopted strategies such as product launches, business expansions, agreements, partnerships, and acquisitions to strengthen their presence in the Leukapheresis market.

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=20283148

Leukapheresis Industry Advantages:

Targeted Cell Collection: Leukapheresis enables precise isolation and collection of specific white blood cell populations, ensuring higher purity and potency of cells for various therapeutic applications.
Personalized Medicine: The technique contributes to personalized medicine by tailoring treatments to individual patients, leveraging their unique genetic profiles for more effective and customized therapies.
Efficiency and Automation: Ongoing innovation and automation within the leukapheresis industry streamline procedures, reducing treatment time, patient discomfort, and optimizing cell yield for improved outcomes.
Consistency and Reliability: Automation ensures consistent cell collection, enhancing reproducibility and reliability in research and clinical applications.
Therapeutic Breakthroughs: Leukapheresis has facilitated advancements in treating diseases like cancer and autoimmune disorders through the development of novel therapies like CAR-T cell therapy.
Research Advancements: The technique supports medical research by providing researchers with purified cell populations for studying disease mechanisms, drug development, and therapy optimization.
Reduced Side Effects: Targeted cell collection minimizes unwanted side effects by focusing only on the specific cell populations needed for treatment.
Minimized Patient Risk: Leukapheresis reduces the need for invasive procedures, lowering patient risk while obtaining essential cells for treatment.
Expanded Treatment Options: The technique expands the range of treatment options available to patients, especially for those with limited alternatives or complex medical conditions.
Clinical Versatility: Leukapheresis finds applications across various medical fields, from cancer and immunology to regenerative medicine, showcasing its versatility in addressing different health challenges.
Pioneering Cellular Therapies: The advancements in leukapheresis techniques have been instrumental in driving the development and success of cutting-edge cellular therapies.
Improved Patient Outcomes: By enhancing the quality and effectiveness of isolated cell populations, leukapheresis contributes to improved patient outcomes and quality of life.
Cost-Effectiveness: In the long term, leukapheresis can offer cost-effective solutions by providing more targeted treatments, potentially reducing the need for extensive and costly interventions.
Medical Progress: The leukapheresis market represents a significant stride toward the future of medicine, fostering innovation and progress in healthcare through its specialized cell collection capabilities.

Recent Developments:

In May 2022, Fresenius Kabi (Germany) acquired Ivenix, Inc. (US). This acquisition adds a next-generation infusion therapy platform for the significant US market to Fresenius Kabi's portfolio and provides the company with key capabilities in hospital connectivity.
In March 2022, Charles River Laboratories International Inc. (US) acquired Retrogenix Limited (UK) to enhance the company's scientific expertise with additional large molecule and cell therapy discovery capabilities.
In November 2021, Discovery Life Sciences (US) announced the launch of the Discovery BIOstore, which provides real-time access to Discovery's inventory of millions of human biospecimens to scientists.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441

Email: [email protected]

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/leukapheresis-market.asp

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/leukapheresis.asp

https://www.prnewswire.com/news-releases/leukapheresis-market-worth-100-million--marketsandmarkets-301914634.html